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Summary
Objectives: A few reports exist on hepatitis B virus (HBV) genotype distribution in Iran; however
the sample sizes of these studies are insufficient. The first objective of this study was to
determine the HBV genotype distribution with a large sample size (147 specimens). The second
objective was to determine the incidence of the lamivudine-resistant YMDDmutant profile among
HBV-infected patients not treated with lamivudine; some studies have reported that YMDD
mutants are detectable even before antiviral treatment.
Methods: Weused twocost-effectivePCR-basedmethods that have beendeveloped in-house: gap-
PCR and artificially created restriction site-PCR (ACRS-PCR). Also, 11 samples were randomly
selected and bi-directionally sequenced and subjected to phylogenetic analysis.
Results: Gap-PCR results revealed genotype D of HBV in all patients, and ACRS-PCR results
disclosed the absence of mutation within the YMDD motif before antiviral therapy in the study
population. Phylogenetic analysis supported the former genotyping results with the segregation of
all Iranian HBV isolates in the genotype D branchwith a high bootstrap value (99%, 1000 replicates).
Conclusions: The present study using two cost-effectivemethods showed that genotypeD of HBV is
dominant among Iranian HBV-infected subjects, and HBV lamivudine-resistant strains do not exist
naturally among Iranian patients not treated with lamivudine.
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Hepatitis B infection has long been a serious public health
problem in the world, and is one the main causes of acute andPublished by Elsevier Ltd. All rights reserved.
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sons are infected chronically with the hepatitis B virus (HBV)
worldwide,1 and it has been demonstrated that chronic
infection with this virus is linked to the development of
hepatocellular carcinoma (HCC).2
Genotypically, HBV has been grouped into eight geno-
types, from A to H, which show distinctive geographical
distribution across the entire world.3 It has been shown that
HBV genotype is associated with certain prognoses, the
clinical picture, and especially the outcome of response to
treatment.4—6
Lamivudine, a nucleoside analogue, has been shown to be
very effective for the treatment of hepatitis B;7 however
viral mutants resistant to this medicine have emerged.8
Lamivudine-resistant HBV has been reported frequently
and is associated with mutations of the YMDD motif in the
HBV polymerase gene.5 It has also been demonstrated that
YIDD and YVDD are the two main types of mutations among
HBV-infected lamivudine-resistant patients.9 However, inter-
estingly, some reports have indicated that YIDD and YVDD
HBV-drug resistant mutants can also be detected in infected
individuals not treated with lamivudine.10,11
Our previous surveys have shown genotype D of HBV and
the wild type YMDD pattern among Iranian populations
infected with the virus,12,13 although the number of patients
enrolled in these studies was small (ca. thirty subjects). In
this study, the study population was increased to 147 HBV-
infected patients to investigate HBV genotype distribution.
Also, the YMDD drug-resistant mutation profile among
infected patients not treated with lamivudine was explored
in order to better understand the variability of the YMDD
motif before antiviral therapy.
Materials and methods
Study population and clinical samples
The study population consisted of individuals referred to
different hospitals in Tehran for various types of operations.
In Iran, according to public health guidelines, those indivi-
duals who undergo any surgical procedures have to be exam-
ined for blood-borne viruses such as HBV, hepatitis C virus
(HCV), and human immunodeficiency virus (HIV). In order to
categorically obtain HBV-infected subjects not treated with
lamivudine, only those operation candidates who were acci-
dentally positive for HBV markers and negative for HCV and
HIVmarkers were enrolled in this survey. The serological tests
were carried out using available ELISA commercial assays
(Abbott Laboratories, North Chicago, IL, USA). The majorityFigure 1 A schematic diagram of the gap-PCR method. The positio
deletions; dots point to similar nucleotides. Each sequence is presente
in detail. The size of amplicon length in genotype D of HBV is arounof these individuals were not aware of their infection, thus
they had not been treated. One hundred forty-seven HBV-
infected blood samples not treated with lamivudine were
collected from several hospitals in Tehran from 2002 to 2006.
Blood samples were centrifuged immediately, and the sera
separated, aliquoted, and then kept frozen at 20 8C until
testing.
Gap-PCR and artificially created restriction
site-PCR (ACRS-PCR)
Sera were thawed and centrifuged at 12 000 rpm for 10 min-
utes; HBV DNA was extracted by the DNGTM-plus DNA extrac-
tion kit (CinnaGen, Tehran, Iran). Genotype D of HBV among
Iranian patients was determined according to Eroglu et al.14
(the gap-PCR method with minor modification in primers and
thermal-cycling program). The primers in this method spe-
cifically distinguish genotype D of HBV from non-D, based on
the specific deletion in the pre-S1 region that occurs natu-
rally in genotype D of HBV. This can be a simple and cost-
effectivemethod for assessing themolecular epidemiology of
HBV, especially in those areas of the world where the geno-
type D of HBV has high prevalence, such as the Middle East
and the Mediterranean countries. Briefly, a pair of primers
was designed (for-D: 50-TGG GAA CAA GAG CTA CAG CAT GG-30
and rev-D: 50-CAA CTG GTG GTC GGG AAA GAA TC-30) in the
two sides of deletion in the genotype D of HBV pre-S1 region
to discriminate genotype D from non-D (Figure 1). After PCR
optimization, the PCR reaction consisted of the following:
1  PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs (Fermentas,
Vilnius, Lithuania), 0.5 mM primer for-D and primer rev-D, 1 U
Taq DNA polymerase (CinnaGen), and 5 ml HBV DNA. The
following PCR thermal-cycling program was carried out:
95 8C for 3 min, 45 cycles consisting of 94 8C for 25 s, 65 8C
for 25 s, and 72 8C for 25 s, followed by 72 8C for 3 min. The
plasmids containing the full genome of HBV genotype D and A
were utilized as controls for the gap-PCR method. Control
plasmids for genotype D were achieved from five complete
genome sequences of Iranian isolates,13 and full-length gen-
ome control plasmids for genotype A of HBV, kindly provided
by Dr Frank Tacke, RWTH-University Hospital Aachen, Ger-
many, were used as a reference control for non-D (A, B, C, E,
F, G, and H) genotypes. In each run, positive and negative
controls were included, and the validity of the results was
assessed by comparing with the values of controls.
ACRS-PCR was carried out by an in-house developed
method with an internal-control digestion that distinguishes
mutations in the YMDD motif as previously described by our
group.15 In brief, three conserved and diagnostic primersn of the primers at the HBV pre-S1 region is depicted. Lines show
d as the consensus of each genotype. Genotype A of HBV is shown
d 80-bp and for non-D (A, B, C, E, F, G, and H) is around 110-bp.
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with certain restriction endonuclease enzymes, and their
reverse primers were also modified in order to monitor
enzyme correctness and to avoid a false outcome. In this
survey, plasmids containing YMDD, YIDD, YVDD, and seven
additional known positive samples with certain YMDD muta-
tions confirmed by INNO-LiPA assay were also applied, as
reported in our previous study.15
Sequencing and phylogenetic analysis
Eleven samples were randomly selected for sequencing and
phylogenetic analysis. Seven samples were the positive con-
trols for YMDD mutants and four samples were selected from
untreated patients. The HBV polymerase gene was intention-
ally chosen for sequencing, not only to verify the YMDD motif
mutation and then ACRS-PCR accuracy, but also to check the
HBV genotype and the validity of the gap-PCR method. After
the amplification of polymerase gene, the amplicons were
purified by Qiaquick PCR purification kit (Qiagen, Hilden,
Germany) and bi-directionally sequenced using the BigDye1
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA) at the Sequence Laboratories Go¨ttingen GmbH
(SEQLAB) in Germany. To perform the phylogenetic analysis,
Iranian HBV genome sequences were compared with those of
different defined HBV strains retrieved from GenBank as
reference genes, as reported previously by Rozanov
et al.16 Alignment was performed by CLUSTAL X program;
genetic distance was calculated using the Kimura two-para-Figure 2 The neighbor-joining phylogenetic analysis of 11 Iranian
other genotype D reference genes branch with 99% bootstrap value (
Iranian isolates have the IR-TMU prefix. The scale bar indicates 2% n
letters.meter algorithm; the phylogenetic tree was constructed by
the neighbor-joining method and bootstrap re-sampling, and
reconstruction was carried out 1000 times to confirm the
reliability of the phylogenetic tree. In this study, MEGA2
software was utilized for phylogenetic and evolutionary
analysis. The HBV gene sequences used in this study were
deposited in GenBank under accession numbers DQ839509—
DQ839519.
Results
The study population consisted of 107 males and 40 females
with a mean age of about 41 years (age range 19—75 years).
Of 147 samples, 125 were successfully amplified for both
genotyping (gap-PCR) and YMDD mutant detection (ACRS-
PCR). Liver function tests were normal as ASTand ALT values
were less than 45 U/l; other liver parameters such as bilirubin
and total protein also had normal values. Laboratory results
revealed that all of the 147 untreated patients could be
categorized as asymptomatic HBV carriers. Serological data
showed that all patients had positive HBsAg status and had
negative serological markers for HCV and HIV.
To determine the genotype, the simple gap-PCR method
was applied, which could readily distinguish the genotype D
of HBV from non-D. The gap-PCR method showed that all HBV
strains isolated from Iranian patients had an 80-bp amplicon,
the specific length for genotype D of HBV, and not the 110-bp
amplicon length of non-D genotype. To confirm the gap-
PCR results, some samples were randomly sequenced andHBV isolates reveals that Iranian isolates are grouped with the
1000 replicates). The bootstrap value below 70% is not shown.
ucleotide divergence. Other HBV genotypes are shown in capital
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Iranian isolates were clustered in the genotype D branch with
other genotype D HBV reference genes (Figure 2). These
isolates branched with genotype D reference isolates with
a 99% bootstrap value (1000 replicates). The phylogenetic
analysis data were completely in agreement with the gap-
PCR results.
In this study, no evidence of mutation in the YMDD motif
among 147 Iranian HBV-infected patients not treated with
lamivudine was determined by the ACRS-PCR assay. The
amino acid comparison results deduced from the polymerase
gene sequences were also in agreement with those of this
method for all 11 patients (seven patients with mutation
(controls) and four untreated patients with wild-type pattern
in the YMDD motif).
Discussion
HBV possesses distinct geographical distribution and clinical
outcomes worldwide. Genotype A is pandemic, but most
prevalent in northwest Europe, North America, and Central
Africa; genotypes B and C are found in East Asia, Korea,
China, and Japan; genotype D is also more or less pandemic,
but is predominant in the Mediterranean area and the Middle
East expanding into India; genotype E is typical of Africa;
genotype G has been found in the USA and France; genotype
H has been reported from Nicaragua, Mexico, and California;
and the origin of genotype F is proposed to be in the New
World because genotype F of HBV is predominant in Central
and South America.17 In the Mediterranean region,18 the
Middle East,19 and in particular, in Iran,12,13 genotype D of
HBV is highly predominant. In this study, a simple and cost-
effective gap-PCR method was developed and utilized to
determine HBV genotype D from non-D. The gap-PCR results
on 147 patients revealed that all Iranian HBV-infected sub-
jects were unsurprisingly infected with genotype D of HBV,
similar to the results of our previous studies with smaller
population sizes.
The advantage of the gap-PCR method is that it is a very
simple and cost-effective method in comparison with the
expensive sequencingmethod, and can be done in all labora-
tories performing routine testing. Of course, it has some
limitations as well. This method is useful only for areas
where genotype D of HBV is predominant, because it distin-
guishes HBV genotype D from non-D. In the case of genotype
non-D detection of HBV by this method, the sample requires
further sequencing in order to determine the HBV genotype.
However, in the endemic genotypeD regions, the rate of non-
D is normally very low; hence, only a few sampleswould need
to be sequenced, leading to a considerable reduction in
costs.
It has been demonstrated that HBV genotype can affect
the clinical outcome of chronic HBV infection.1 For instance,
genotype D of HBV is associated with more severe liver
disease than genotype A and may lead to HCC in young
patients.6,20 It has also been reported that genotype D of
HBV has a lower response rate to lamivudine in comparison
with genotype A of HBV.21 Therefore, understanding of HBV
genotype distribution seems to be highly important for the
better management of HBV infection by medical personnel
and for the improvement of public health.Lamivudine inhibits viral DNA polymerase in HBV and can
be effective for rapidly reducing the serum HBV DNA titer.7
However, lamivudine resistance among HBV-infected
patients during therapy has been reported (as much as
10—45% during the first year of treatment).22 It has been
demonstrated that the emergence of lamivudine-resistant
HBV is associated with mutations of the YMDD motif within
the conserved sub-domain C in the polymerase gene.9 Inter-
estingly, lamivudine-resistant mutants have been reported
among patients not treated with lamivudine with a range of
1—27%.10,11,23—26 It has been shown that there exists a rela-
tionship between HBV genotypes and YMDD mutant profile in
untreated patients. Horgan and coworkers revealed that
among untreated patients, genotype D of HBV had no muta-
tion in the YMDD motif, whereas untreated patients with
genotype C of HBV had mutations in the YMDD motif.26
Antiviral drug resistance is currently a major problem in
the management of patients with chronic HBV infection. It
has been demonstrated that the mutation in the YMDD motif
can directly affect HBV replication and may affect the out-
come of the disease. For example, it has been verified that
the precore (A1896A) and, in particular, basic core promoter
mutations (A1762T/G1764A) result in increased replication
capacities together with lamivudine-resistant mutations
compared with those of wild-type virus. Likewise, it has
been revealed that the combination of lamivudine-resistant
mutations with the ‘a’ determinant mutation has enhanced
the replication of the virus as well.27 Moreover, because of
the proximity of the pol-gene and the S-gene in HBV genome;
mutations in the pol-gene can also alter the envelope gene
sequence and consequently may result in vaccine escape or
diminished HBsAg secretion.27 Therefore, because of the
importance of drug-resistant strains in the treatment strat-
egy, we explored the rate of YMDD mutants among untreated
patients in this study; the result of the ACRS-PCR method
revealed no mutation among Iranian subjects not treated
with lamivudine. Hence, further investigations need to be
carried out to understand whether lamivudine-resistant HBV
can naturally exist in other populations of HBV untreated
patients.
This survey revealed that HBV genotype D is dominant in
Iran, and no YMDD mutation was found among HBV-infected
patients not treated with lamivudine in Iran, using simple and
cost-effective methods. These methods can easily be
employed in general clinical laboratories for the screening
of large numbers of individuals who are living in HBV geno-
type D prevalent areas of the world.
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